uniQure Strengthens Intellectual Property Portfolio with Granted Patent Claims Covering AMT-130 for Huntington’s Disease
May 22, 2019 07:00 ET
|
uniQure Inc.
~ Issued Patents in the U.S. and EU Cover RNA Construct Specifically Designed to Target Highly Toxic Exon1 Protein ~ LEXINGTON, Mass. and AMSTERDAM, the Netherlands, May 22, 2019 (GLOBE NEWSWIRE)...
uniQure Announces Featured Presentations of New Data on Spinocerebellar Ataxia Type 3 at the 2019 American Academy of Neurology Annual Meeting
May 07, 2019 07:00 ET
|
uniQure Inc.
~ Data Show AMT-150 Able to Significantly Lower Mutant Ataxin-3 Protein in SCA3 Disease Model ~ ~ Provides Further Support of Proof-of-concept of Company’s Proprietary miQURE™ Gene Silencing...
uniQure Highlights Pipeline Expansion and Advancements in Technology at Research & Development Day
November 19, 2018 12:15 ET
|
uniQure Inc.
~ Unveils New AAV Gene Therapy Approaches to Hemophilia A, Fabry Disease and Spinocerebellar Ataxia Type 3 ~ ~ Introduces miQURE™ Gene Silencing Platform with Applications Across Multiple Indications...